About Us

Eluminex is committed towards developing first- and/or best-in-class innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in China and global markets.

Eluminex Biosciences is a privately held ophthalmology-focused biotechnology company founded in early 2020. The leadership team comprises over 100 years of cumulative global drug development experience in ophthalmology with a longstanding track record of success. Our expertise allows for evaluation of therapeutic opportunities for both anterior and posterior segment diseases. Our company headquarters and research and development (R&D) facility is located in Suzhou BioBAY, China and our US regional office is located in the biotech corridor of South San Francisco, California in the San Francisco Bay Area.

We have established a state-of-the-art R&D facility in the Suzhou BioBAY.  The nearly 24,000 square feet (2,200 sqm) R&D center will allow the full range of basic science research and drug discovery, formulation development, and validating preclinical/chemistry, manufacturing and control (CMC) studies in support of investigational new drug applications (IND) for small molecules, proteins, drug delivery, and regenerative medicine.

Eluminex Biosciences location at Suzhou BioBay headquarters and interior design.

Eluminex Biosciences San Francisco Bay Area Office.

Message from the CEO

I am pleased to report that we begin 2023 from a position of strength. First, we recently closed over $40M Series B round that will enable us to further mature our innovative pipeline of ocular and recombinant collagen-based therapeutics. Second, we began enrollment of the pivotal CLARITY study that potentially may lead to the world’s first approved biosynthetic cornea in humans.

We have made substantial progress since our $50 million Series A closure in November 2020 which has led to the development of 6 pipeline programs. The Series B raise gives us significant momentum to move additional programs into the clinic over the next several months and strengthen our position in developing novel multi-target therapeutics for retinal diseases and developing collagen-based products. With our world class capabilities in the manufacturing and development of recombinant human collagen, acquired from FibroGen, the CLARITY study of our EB-301 corneal implant opens the possibility of a new option for restoring vision in patients who cannot receive a corneal transplant due to worldwide shortage of donor tissue. Our overall goal as a company remains to make a difference for patients around the world who can benefit from our unique pipeline of recombinantly-engineered proteins for vision-threatening diseases and other significant unmet needs.

Jinzhong (JZ) Zhang, PhD